---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-001542"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T19:10:01.065843+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Coherus Biosciences appoints Georgia Erbez to Board of Directors

## Summary
- Board expanded from 9 to 10 directors; Erbez appointed as Class III director until 2026 annual meeting.
- Erbez also named to audit committee; has served as Managing Director of Axiom Financial Partners since 2014.
- Non-employee director: receives $50,000 annual cash retainer and option to purchase 54,000 shares vesting over 3 years.
- Previous roles include CFO of Harpoon Therapeutics and COO of Walking Fish Therapeutics.

## SEC filing metadata
- accession: 0001558370-24-001542
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837024001542/0001558370-24-001542-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837024001542/chrs-20240220x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-001542
- JSON: https://secwatch.observer/filing/0001558370-24-001542.json
- Plain text: https://secwatch.observer/filing/0001558370-24-001542.txt

## Key facts
- Executive change
  Georgia Erbez was appointed as Class III Director at Coherus Oncology, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: On February 20, 2024, the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), increased the size of the Board from nine directors to ten directors and approved, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the appointment of Georgia Erbez to serve as a Class III director to fill the vacancy created by such increase.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837024001542/0001558370-24-001542-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.